Izalontamab SI-B001 shows an significant step forward in hematologic treatment of difficult-to-treat multiple myeloma. This unique antibody directly targets BCMA on myeloma cells, triggering antibody-dependent cellular cytotoxicity and promoting cancer-inhibiting body's reactions. Preliminary patient results suggests substantial remissions and the